BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 20921397)

  • 21. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals.
    Iacono-Connors LC; Welkos SL; Ivins BE; Dalrymple JM
    Infect Immun; 1991 Jun; 59(6):1961-5. PubMed ID: 1903769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of a capsule conjugate vaccine against inhalational anthrax in rabbits and monkeys.
    Chabot DJ; Joyce J; Caulfield M; Cook J; Hepler R; Wang S; Vietri NJ; Ruthel G; Shoop W; Pitt L; Leffel E; Ribot W; Friedlander AM
    Vaccine; 2012 Jan; 30(5):846-52. PubMed ID: 22172509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Significant passive protective effect against anthrax by antibody to Bacillus anthracis inactivated spores that lack two virulence plasmids.
    Enkhtuya J; Kawamoto K; Kobayashi Y; Uchida I; Rana N; Makino SI
    Microbiology (Reading); 2006 Oct; 152(Pt 10):3103-3110. PubMed ID: 17005989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses.
    Belyakov IM; Earl P; Dzutsev A; Kuznetsov VA; Lemon M; Wyatt LS; Snyder JT; Ahlers JD; Franchini G; Moss B; Berzofsky JA
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9458-63. PubMed ID: 12869693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Bivalent Anthrax-Plague Vaccine That Can Protect against Two Tier-1 Bioterror Pathogens,
    Tao P; Mahalingam M; Zhu J; Moayeri M; Kirtley ML; Fitts EC; Andersson JA; Lawrence WS; Leppla SH; Chopra AK; Rao VB
    Front Immunol; 2017; 8():687. PubMed ID: 28694806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.
    Stokes MG; Titball RW; Neeson BN; Galen JE; Walker NJ; Stagg AJ; Jenner DC; Thwaite JE; Nataro JP; Baillie LW; Atkins HS
    Infect Immun; 2007 Apr; 75(4):1827-34. PubMed ID: 17145938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A putative exosporium lipoprotein GBAA0190 of Bacillus anthracis as a potential anthrax vaccine candidate.
    Jeon JH; Kim YH; Kim KA; Kim YR; Woo SJ; Choi YJ; Rhie GE
    BMC Immunol; 2021 Mar; 22(1):20. PubMed ID: 33743606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
    McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
    J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with Bacillus anthracis Ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen.
    Peachman KK; Rao M; Alving CR; Burge R; Leppla SH; Rao VB; Matyas GR
    Infect Immun; 2006 Jan; 74(1):794-7. PubMed ID: 16369043
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
    Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH
    PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against
    Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R
    Front Immunol; 2019; 10():498. PubMed ID: 30941133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
    Baillie LW; Rodriguez AL; Moore S; Atkins HS; Feng C; Nataro JP; Pasetti MF
    Vaccine; 2008 Nov; 26(48):6083-91. PubMed ID: 18805452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multipathogen DNA vaccine elicits protective immune responses against two class A bioterrorism agents, anthrax and botulism.
    Kim NY; Son WR; Lee MH; Choi HS; Choi JY; Song YJ; Yu CH; Song DH; Hur GH; Jeong ST; Hong SY; Shin YK; Shin S
    Appl Microbiol Biotechnol; 2022 Feb; 106(4):1531-1542. PubMed ID: 35141866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.
    Williamson ED; Hodgson I; Walker NJ; Topping AW; Duchars MG; Mott JM; Estep J; Lebutt C; Flick-Smith HC; Jones HE; Li H; Quinn CP
    Infect Immun; 2005 Sep; 73(9):5978-87. PubMed ID: 16113318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.
    Lee JS; Hadjipanayis AG; Welkos SL
    Infect Immun; 2003 Mar; 71(3):1491-6. PubMed ID: 12595467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccines and bioterrorism: smallpox and anthrax.
    Kimmel SR; Mahoney MC; Zimmerman RK
    J Fam Pract; 2003 Jan; 52(1 Suppl):S56-61. PubMed ID: 12556279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced Immune Response to DNA Vaccine Encoding Bacillus anthracis PA-D4 Protects Mice against Anthrax Spore Challenge.
    Kim NY; Chang DS; Kim Y; Kim CH; Hur GH; Yang JM; Shin S
    PLoS One; 2015; 10(10):e0139671. PubMed ID: 26430894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy.
    Wittek R
    Int J Infect Dis; 2006 May; 10(3):193-201. PubMed ID: 16564720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.